Market closedNon-fractional
Anika Therapeutics/ANIK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Anika Therapeutics
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Ticker
ANIK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Bedford, United States
Employees
357
Website
www.anika.com
ANIK Metrics
BasicAdvanced
$377M
Market cap
-
P/E ratio
-$5.24
EPS
0.73
Beta
-
Dividend rate
Price and volume
Market cap
$377M
Beta
0.73
Financial strength
Current ratio
5.585
Quick ratio
3.539
Long term debt to equity
12.633
Total debt to equity
13.654
Management effectiveness
Return on assets (TTM)
-1.81%
Return on equity (TTM)
-31.61%
Valuation
Price to revenue (TTM)
2.198
Price to book
1.79
Price to tangible book (TTM)
1.89
Price to free cash flow (TTM)
-89.803
Growth
Revenue change (TTM)
7.49%
Earnings per share change (TTM)
242.17%
3-year revenue growth
9.38%
3-year earnings per share growth
40.48%
What the Analysts think about ANIK
Analyst Ratings
Majority rating from 3 analysts.
ANIK Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
-5.59%
Net income
-$4.5M
-92.86%
Profit margin
-11.11%
-92.43%
ANIK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.45
-$4.30
-$0.31
-
Expected
-$0.27
-$0.37
-$0.26
-$0.19
$0.05
Surprise
-29.63%
20.54%
1,532.91%
66.07%
-
ANIK News
AllArticlesVideos
Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research
GlobeNewsWire·5 days ago
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Anika Enters into Cooperation Agreement with Caligan Partners
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anika Therapeutics stock?
Anika Therapeutics (ANIK) has a market cap of $377M as of July 06, 2024.
What is the P/E ratio for Anika Therapeutics stock?
The price to earnings (P/E) ratio for Anika Therapeutics (ANIK) stock is 0 as of July 06, 2024.
Does Anika Therapeutics stock pay dividends?
No, Anika Therapeutics (ANIK) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Anika Therapeutics dividend payment date?
Anika Therapeutics (ANIK) stock does not pay dividends to its shareholders.
What is the beta indicator for Anika Therapeutics?
Anika Therapeutics (ANIK) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Anika Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.